Compare American Airlines Group Inc (AAL) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Airlines Group Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? American Airlines Group Inc trades at $15.37 (market cap $10.55B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B). The key difference: American Airlines Group Inc and Bio-Rad Laboratories, Inc. Class A Common Stock are close in size by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, American Airlines Group Inc nearer its low. Which is the better fit depends on your goals.
| AAL | BIO | |
|---|---|---|
Market Cap | $10.55B | $9.39B |
Sector | Industrials | Health |
52-Week High | $18.15 | $356.25 |
52-Week Low | $10.18 | $241.71 |
Enterprise Value | $38.51B | $9.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAL trades at $15.94, down 0.56% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025. Revenue growth is steady, reaching $54.63 billion in 2025, though net income margins are thin at 0.2%. Debt-to-asset ratios have improved to 47.25% in 2025, but negative shareholder equity remains a concern. Recent news highlights advancements in sustainable aviation fuel and premium revenue growth.
The outlook is cautiously optimistic, supported by analyst consensus favoring buy ratings (44.74%) and a $19.63 price target, implying 23% upside. Key opportunities include robust premium demand and cost management, while risks involve fuel cost volatility, high debt, and competitive pressures. Earnings execution and fuel price trends will be critical for sustained stock performance.
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
